The pharmaceutical industry wasn’t directly represented at the White House’s pharmacy benefits management roundtable on 4 March, but their agenda – to put the onus of drug affordability challenges on PBMs – took center stage, offered by actors who likely make the industry’s messages more palatable.
The big three PBMs, as they were called during the discussion titled to “bring transparency to prescription drug middlemen,” weren’t...